Objective: This document summarizes the limited experience of SARS in pregnancy and suggests guidelines for management.
INTRODUCTION
S evere acute respiratory syndrome, or SARS, emerged as a highly contagious and life-threatening condition in 2003. By the end of 2003, a total of 8096 cases had been identified internationally, and 774 deaths were reported. 1 Although the majority of cases occurred in South East Asia, 251 probable cases, 187 suspected cases, and 43 deaths were reported in Canada as of September 2003. 2 It is now known that SARS is caused by a novel coronavirus [3] [4] [5] and is easily spread by respiratory droplets and nosocomial contact. 6, 7 Evidence suggests that health care facilities are the major source for new SARS infections; this was a major factor in the so-called "second wave" of SARS infections in April and May 2003 in the Greater Toronto Area. During this period, affected patients from outlying areas were transferred to a designated tertiary care hospital for treatment in order to limit the number of institutions with active SARS cases. Fortunately, only one case of SARS occurring in pregnancy was reported in Canada. 8 This document summarizes the limited information available regarding SARS in pregnancy and suggests strategies for managing pregnant women and their families in the antenatal, labour and delivery, and postnatal settings. The approach and recommendation of this document may be helpful in creating protocols for other new airborne viral infections.
HISTORY OF THE SARS EPIDEMIC
In February 2003, the first cases of SARS in Canada, presenting as an atypical pneumonia, occurred in the Toronto area. All cases that subsequently occurred in the region can be traced to one of the individuals first affected. 6 Similar outbreaks were reported in Hong Kong, 9 Vietnam, 10 Singapore, 11 Thailand, 12 and Taiwan. 13 The diagnosis of SARS was based on viral testing in combination with several clinical findings. 1, 14 TREATMENT AND PREVENTION STRATEGIES Health Canada has outlined the following basic principles for management and treatment of SARS in non-pregnant individuals, as well as recommended testing for SARS. 14
Clinical Features, Treatment and Outcome in Non-Pregnant SARS Patients
In a study of 144 patients with SARS from the Greater Toronto Area, most patients were exposed in the hospital setting (77%). 15 These individuals included health care workers, patients, and visitors to the hospital. The median time from self-reported exposure to onset of symptoms was 6 to 9 days. Almost all patients received empirical antibiotic therapy (95%) and ribavirin (88%). Forty percent of patients received steroids.
Of the 20% of patients admitted to the intensive care unit (ICU), 69% required mechanical ventilation. There were 8 deaths, or a 6.5% mortality rate. Predictors of poor outcome (death or admission to the ICU) included increased age, male sex, diabetes, increased neutrophil count, creatine kinase, and urea. In a separate study assessing the outcomes of critically ill patients with SARS in the Toronto area, investigators found that 76% required mechanical ventilation. 16 Among those requiring ventilation, the mortality rate was 45%. In this study, transmission of SARS within 6 of the intensive care units that were evaluated prompted closure of 73 medical-surgical ICU beds, leading to 164 health care workers being placed in quarantine.
Effects of SARS in Pregnancy

Pulmonary infections in pregnancy
The most common non-obstetric infection during pregnancy is pneumonia, [17] [18] [19] and in a series of studies, it is the third most common cause of indirect obstetric death. 20 In the pre-antibiotic era, maternal mortality was as high as 30% 21 ; more recently, it is reported to be less than 10%. 18, 19 Nonetheless, approximately 25% of pregnant patients with pneumonia will require ventilatory support in a critical care unit. 18 Viral pneumonia is associated with higher morbidity and mortality than bacterial pneumonia responsive to antibiotics. 22 Physiologic changes in pregnancy, including altered cell-mediated immunity 23 and alterations in pulmonary function, [24] [25] [26] are hypothesized to affect the susceptibility to and severity of pneumonia.
The most detailed reports of viral pneumonia are of cases caused by influenza or varicella.
The influenza epidemic of 1918 had a maternal mortality rate of 30% to 50%. 27, 28 During the 1957-1958 Asian flu epidemic, the maternal mortality rate was twice that of non-pregnant women, with a higher rate in the third trimester. 29 Ten percent of all deaths related to this influenza epidemic were in pregnant women. 27 The most common fetal complications arising from maternal pneumonia include prematurity resulting from preterm labour (up to 44%), intrauterine growth restriction (up to 12%), intrauterine demise (up to 3%), and neonatal demise (up to 12%). [17] [18] [19] Furthermore, mid-trimester exposure to certain viruses (such as varicella) may cause embryopathy and multiple congenital anomalies. 30, 31 
SARS Cases Reported in Pregnancy
By May 2003, a total of 10 cases of SARS had been reported in pregnant patients from Hong Kong. 32 Hypoxia, resulting from SARS-related acute respiratory distress syndrome, led to early pregnancy loss in 4 of the 10 cases. To help protect the fetus, pregnant women were given supplemental oxygen to maintain maternal arterial saturation above 95%, and kept in an upright position. Women receiving mechanical ventilation were maintained in the left lateral position to maximize uterine blood flow. Fetal status was monitored using cardiotocography, and ultrasound examination was used to monitor growth and Doppler flows.
All pregnant patients were treated empirically with broad-spectrum antibiotics (e.g., clarithromycin, amoxicillin-clavulanate) to prevent secondary bacterial infections. Ribavirin was reserved for patients with the most severe forms of the illness. As there is no evidence for ribavirin being effective in treating SARS, it is currently not recommended. 14 High dose pulse corticosteroids were administered in several cases. 33 Two deaths occurred in pregnant patients receiving high dose steroids in association with multi-drug resistant Staphylococcus aureus (MRSA) septicemia. The pregnant women thought to be at risk for preterm birth were given additional dexamethasone as prophylaxis for the fetus.
Pregnant patients with SARS were isolated from other antenatal and postnatal patients. A small core group of personnel were assigned to care for these patients exclusively, and all used strict respiratory precautions (such as the use of N95 masks or the equivalent), special gowns, and negative air pressure circulation at all times.
The outcomes in pregnant SARS patients in Hong Kong appeared to be worse than outcomes in their non-pregnant counterparts. Of the seven cases followed at the designated SARS unit, two died (28%), and four (57%) were admitted to intensive care for mechanical ventilation. This is in contrast to mortality rates of less than 10% and mechanical ventilation rates of less than 20% in non-pregnant, age-matched counterparts. Fortunately, there was no clinical or laboratory evidence of SARS in any of the babies delivered in this series.
No conclusions could be drawn about the safety of planned early delivery by the vaginal route compared with Caesarean delivery, or regional anaesthesia compared with general anaesthesia. However, for the most severe cases, Caesarean delivery and general endotracheal anaesthesia were elected in order to avoid emergency airway issues and to minimize exposure risk for others. As with mothers infected with HIV, SARS-affected patients were advised against breastfeeding in case of possible vertical transmission of the virus.
Antivirals Used to Treat SARS in Pregnancy
There is no evidence that ribavirin is effective in the treatment of coronaviruses or SARS. 15, 34, 35 Furthermore, there is evidence of severe toxicity in SARS patients as a result of treatment with ribavirin. 36 In Canada, ribavirin is no longer recommended for treatment of SARS. 14 In vitro evidence suggests a role for the use of human recombinant interferons a, b, and g in the treatment of SARS. 37, 38 Their use in the clinical setting of SARS in pregnancy requires further investigation.
Institutional and Personnel Issues in the Care of Pregnant SARS Patients
A review of the Hong Kong experience provides important information. For example, all pregnant patients with SARS were managed in one unit at a designated maternity hospital. At one institution with a referral-based obstetrics and gynaecology service, the administration coordinated a transfer arrangement of SARS patients to the designated SARS hospital. 39 All non-urgent ambulatory and elective gynaecological/surgical services were suspended.
The overall number of staff was limited, and only a specific subgroup was assigned to the care of SARS pregnant patients. Communications among medical personnel were by phone or by electronic mail, and teaching conferences were suspended. Clinical teaching was limited to avoid unnecessary exposures. Infection control teaching modules were developed for all obstetrical staff, and all workers were routinely screened for symptoms and signs of infection.
Suggested Management Guidelines for Pregnant Women With Confirmed SARS
Labour triage and antenatal hospital admission
Actions
• Assessment is made as to whether the patient has suspected or probable SARS 1, 14 • Upon arrival in the labour and delivery triage unit, pregnant patients presenting with fever > 38°C and respiratory symptoms and one of the associated symptoms (cough, unexplained hypoxia, shortness of breath, or dyspnea) and history of an exposure to an individual with probable SARS are immediately transferred to the designated isolation room, which is equipped with negative pressure ventilation. This may be a SARS unit in the case of epidemic exposures. If necessary, procedures and delivery may be performed in this isolation room • To minimize neonatal transmission risk, the mother should be isolated from the neonate until she has recovered from SARS and is considered no longer infectious Communications • Support should be given to the mother and her family to cope with separation from her neonate, potential prolonged maternal hospitalization, parenting issues, neonatal nutrition, and breast engorgement • As separation of mother and neonate may last for less than 10 days, breast pumping is recommended so that breastfeeding may begin once isolation has been discontinued formula should be used until the mother is considered no longer infectious.
Communications
• Parents and family are counselled to look for symptoms and signs of SARS in the mother and newborn, especially in the first 10 days following delivery • Support should be given to the mother and her family to cope with separation from her neonate, potential prolonged maternal hospitalization, parenting issues, neonatal nutrition, and breast engorgement • As separation of mother and neonate may last for less than 10 days, breast pumping is recommended so that breastfeeding may begin once isolation has been discontinued
Neonatal resuscitation
Actions
• Neonates born to mothers with potential SARS close contact are considered to be potentially infectious until 10 days postpartum • Preliminary testing for SARS is performed on the neonate only if mother or neonate has symptoms or signs of SARS • If the mother remains asymptomatic, consider discharge of the neonate with the mother Communications • Parents and family are counselled to look for symptoms and signs of SARS in the mother and newborn, especially in the first 10 days following delivery, and to report to any findings to the health care team SUMMARY SARS, a life-threatening respiratory illness caused by a novel coronavirus, was responsible for a worldwide outbreak in 2003. SARS has been responsible for serious illness in over 250 Canadians and for 43 deaths since 2003. Given the highly infectious nature of SARS, diagnosis, treatment and containment procedures must be aggressively pursued in all medical communities to prevent epidemic spread. Special consideration must be given to the labour and delivery ward where mothers, their babies, and families are potentially placed at risk by exposure to an infected individual. In addition, special procedures must be instituted to protect labour and delivery personnel, who may have prolonged contact with labouring women and substantial exposure to body fluids at the time delivery and neonatal resuscitation. This document outlines a suggested management strategy for pregnant patients with SARS on the labour and delivery ward. This protocol may be of use for other emerging life-threatening infectious diseases.
Recommendations
The quality of evidence reported in this document has been assessed using the Evaluation of Evidence criteria in the Report of the Canadian Task Force on Preventive Health Care (Table) . 4. If possible, labour and delivery (including operative delivery or Caesarean section) should be managed in a designated negative pressure isolation room, by designated personnel with specialized infection control preparation and protective gear. (III-C) 5. Either regional or general anaesthesia may be appropriate for delivery of patients with SARS. (III-C) 6. Neonates of mothers with SARS should be isolated in a designated unit until the infant has been well for 10 days, or until the mother's period of isolation is complete. The mother should not breastfeed during this period. (III-C) 7. A multidisciplinary team, consisting of obstetricians, nurses, pediatricians, infection control specialists, respiratory therapists, and anaesthesiologists, should be identified in each unit and be responsible for the unit organization and implementation of SARS management protocols. (III-C) 
